# Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Source: https://onco.cc/trials/nct07359404/  
OnCo record `nct07359404` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan and bevacizumab in triple-negative breast cancer, run by YING FAN, now recruiting.

## Summary

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC is a phase 2, interventional study registered as NCT07359404 by YING FAN, with a registry enrolment figure of 60 participants, started 2024-04-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Sacituzumab Govitecan (SG); Bevacizumab. Conditions listed: Advanced Breast Cancer. Triple-negative eligibility wording from the registry: "Pathologically confirmed recurrent or metastatic Triple-Negative Breast Cancer (TNBC)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07359404
- Phase: 2
- Setting: A Phase II Clinical Study of Sacituzumab Govitecan Combined With Bevacizumab for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer
- Sponsor: YING FAN
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07359404: https://clinicaltrials.gov/study/NCT07359404

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07359404.json